Monthly Archives: December 2012
Italian myelofibrosis expert Dr. Giovanni Barosi, discusses the tests that aid in diagnosis of mylofibrosis and prognosis for treatment. He also explains how the Jak-2 V617F mutation is useful in helping to diagnose the condition. Barosi elaborates on various types of clinical follow-up used to monitor patients including cell counts,… Continue reading
BKoffman.BlogSpot.com At the American Society of Hematology Annual Meeting, Atlanta, Georgia in December 2012, Dr. Brian Koffman interviews journalist, patient advocate, and web-savvy patient, Andrew Schorr (www.patientpower.info concerning his own personal challenges and successes with chronic lymphocytic leukemia (CLL) and myelofibrosis. Learn from Andrew his strategies for coping with cancer… Continue reading
Mayo Clinic expert, Dr. Ruben Mesa provides an update from the 2012 American Society of Hematology Meeting on important news for patients living with Myelofibrosis. He talks about where we are in understanding myeloproliferative disorders and what genetic changes patients experience that could potentially predict the behavior of the disease.… Continue reading
Myelofibrosis control tissues in the spleens of patients with this disorder might sustain difference programs equivalent to those located in normal hematopoietic control tissues, based on research outcomes.
The researchers carried out the study to establish the effects of innate qualities of and regulating alerts supplied by the microenvironment in… Continue reading
From Healio.com, Moshe Talpaz, MD, associate chief of the division of hematology/oncology at the University of Michigan Comprehensive Cancer Center, discusses results of a phase 2 study of SAR302503, an investigational selective JAK2 inhibitor. The findings suggest the treatment was associated with reductions in spleen size and improved constitutional symptoms… Continue reading
A quote for you...
Powered By Optimism Quotes
12/09/2012| 10:21am US/Eastern
Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint – New Data Presented at American Society of Hematology Annual Meeting Show Activity Against Disease and Symptom Alleviation –
Paris, France – December 9, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY)… Continue reading
Things are changing in myelofibrosis. As researchers better understand the genetics of the condition, they are working to develop new drugs to reduce or eliminate side affects of the illness and treat the underlying condition in a patient’s blood cell factory, the bone marrow. A leading scientist and clinician in… Continue reading
Patients who have suffered before with the significant symptoms of myelofibrosis – scarring in the bone marrow – can take heart that a new, approved medicine, Ruxolitinib (brand name Jakafi), is helping many patients return to a fuller life. Dr. Srdan Verstovsek, a myelofibrosis expert at MD Anderson Cancer Center… Continue reading
The landscape of care is changing for patients with myelofibrosis. A new drug, that experts say can significantly improve symptoms for many patients, has been recently approved while significant research is underway to better manage the progressive scarring in the bone marrow which is at the root of the condition.… Continue reading